Distribution of functional opioid receptors in human dorsal root ganglion neurons.


Journal

Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 27 2 2020
medline: 15 5 2021
entrez: 27 2 2020
Statut: ppublish

Résumé

Preclinical evidence has highlighted the importance of the μ-opioid peptide (MOP) receptor on primary afferents for both the analgesic actions of MOP receptor agonists, as well as the development of tolerance, if not opioid-induced hyperalgesia. There is also growing interest in targeting other opioid peptide receptor subtypes (δ-opioid peptide [DOP], κ-opioid peptide [KOP], and nociceptin/orphanin-FQ opioid peptide [NOP]) on primary afferents, as alternatives to MOP receptors, which may not be associated with as many deleterious side effects. Nevertheless, results from several recent studies of human sensory neurons indicate that although there are many similarities between rodent and human sensory neurons, there may also be important differences. Thus, the purpose of this study was to assess the distribution of opioid receptor subtypes among human sensory neurons. A combination of pharmacology, patch-clamp electrophysiology, Ca imaging, and single-cell semiquantitative polymerase chain reaction was used. Our results suggest that functional MOP-like receptors are present in approximately 50% of human dorsal root ganglion neurons. δ-opioid peptide-like receptors were detected in a subpopulation largely overlapping that with MOP-like receptors. Furthermore, KOP-like and NOP-like receptors are detected in a large proportion (44% and 40%, respectively) of human dorsal root ganglion neurons with KOP receptors also overlapping with MOP receptors at a high rate (83%). Our data confirm that all 4 opioid receptor subtypes are present and functional in human sensory neurons, where the overlap of DOP, KOP, and NOP receptors with MOP receptors suggests that activation of these other opioid receptor subtypes may also have analgesic efficacy.

Identifiants

pubmed: 32102022
doi: 10.1097/j.pain.0000000000001846
pmc: PMC7305987
mid: NIHMS1562598
pii: 00006396-202007000-00020
doi:

Substances chimiques

Analgesics, Opioid 0
Opioid Peptides 0
Receptors, Opioid 0
Receptors, Opioid, kappa 0
Receptors, Opioid, mu 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1636-1649

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS096705
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK107966
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069951
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS073548
Pays : United States
Organisme : NINDS NIH HHS
ID : F32 NS110148
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS083347
Pays : United States
Organisme : NIDCR NIH HHS
ID : R21 DE027873
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR063772
Pays : United States
Organisme : NINDS NIH HHS
ID : F32 NS103231
Pays : United States

Références

Clin J Pain. 2010 Jan;26 Suppl 10:S10-5
pubmed: 20026960
J Pharmacol Exp Ther. 2006 Feb;316(2):772-9
pubmed: 16258020
Pain. 2014 Sep;155(9):1861-1870
pubmed: 24973718
Pain. 2018 Jul;159(7):1325-1345
pubmed: 29561359
J Biol Chem. 2012 Dec 7;287(50):41595-607
pubmed: 23086943
J Biol Chem. 2009 Jan 23;284(4):1990-2000
pubmed: 19029294
J Neurosci. 2015 Sep 30;35(39):13487-500
pubmed: 26424893
J Pharmacol Exp Ther. 1991 Jul 1;258(1):299-303
pubmed: 1649297
J Biol Chem. 2011 Sep 9;286(36):31731-41
pubmed: 21757712
J Neurosci. 1991 Apr;11(4):928-32
pubmed: 2010815
Mol Pain. 2013 Dec 26;9:67
pubmed: 24369063
Neurosci Lett. 1994 Feb 28;168(1-2):97-100
pubmed: 8028801
Brain. 2019 May 1;142(5):1215-1226
pubmed: 30887021
Trends Pharmacol Sci. 1990 Feb;11(2):70-6
pubmed: 2156363
Elife. 2017 May 16;6:
pubmed: 28508747
Br J Pharmacol. 2015 Jul;172(13):3302-12
pubmed: 25752320
J Neurosci. 2017 Apr 5;37(14):3741-3752
pubmed: 28264976
ACS Chem Neurosci. 2012 Jul 18;3(7):505-9
pubmed: 22860219
Neurosci Bull. 2018 Feb;34(1):4-12
pubmed: 28424991
Expert Opin Investig Drugs. 2017 Feb;26(2):155-160
pubmed: 28001096
J Neurosci. 2016 Oct 19;36(42):10769-10781
pubmed: 27798132
Cell. 2009 Jun 12;137(6):1148-59
pubmed: 19524516
Neurosci Lett. 1996 Jul 12;212(2):83-6
pubmed: 8832644
Neuroscience. 1998 Feb;82(4):1225-42
pubmed: 9466442
J Neurophysiol. 1994 Oct;72(4):1549-60
pubmed: 7823085
Eur J Pharmacol. 1985 Aug 27;114(3):241-6
pubmed: 2415368
J Pain. 2019 Jul;20(7):810-818
pubmed: 30659887
J Pharmacol Exp Ther. 2004 Dec;311(3):939-47
pubmed: 15280436
Cell Signal. 2017 Apr;32:59-65
pubmed: 28088389
J Neurosci. 1997 Oct 15;17(20):8018-23
pubmed: 9315920
Cell. 2011 Mar 18;144(6):897-909
pubmed: 21414482
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13117-22
pubmed: 20615975
Neuropsychopharmacology. 2009 Aug;34(9):2088-96
pubmed: 19279568
Pain. 2002 Sep;99(1-2):111-20
pubmed: 12237189
J Neurophysiol. 1995 May;73(5):1793-8
pubmed: 7623080
Eur J Pain. 2007 Feb;11(2):192-201
pubmed: 16542859
Br J Pharmacol. 2015 Jan;172(2):317-23
pubmed: 24528283
Science. 1995 Nov 24;270(5240):1366-9
pubmed: 7481826
Neuropeptides. 1989 Oct;14(3):151-9
pubmed: 2559354
Brain Res. 1982 May 6;239(1):315-21
pubmed: 7093688
eNeuro. 2018 Apr 13;5(2):
pubmed: 29662945
Adv Pharmacol. 2016;75:217-43
pubmed: 26920014
J Chem Neuroanat. 2005 Jun;29(4):255-64
pubmed: 15927787
Brain Res. 1993 Apr 2;607(1-2):314-8
pubmed: 8481806
Neuroscience. 1989;32(3):571-5
pubmed: 2557556
Neuron. 2014 Mar 19;81(6):1443
pubmed: 28898633
Science. 1995 Nov 3;270(5237):792-4
pubmed: 7481766
J Neurosci. 2019 Jan 16;39(3):393-411
pubmed: 30459229
Nature. 1997 Jan 30;385(6615):442-6
pubmed: 9009192
Sci Signal. 2018 Jul 17;11(539):
pubmed: 30018083
J Pharmacol Exp Ther. 1987 Oct;243(1):258-63
pubmed: 2822900
Neuron. 1995 Oct;15(4):929-40
pubmed: 7576641
Handb Exp Pharmacol. 2015;226:291-314
pubmed: 25861786
Neuron. 1993 Feb;10(2):127-36
pubmed: 8382496
J Neurosci. 1993 Feb;13(2):867-73
pubmed: 7678862
Life Sci. 2010 Apr 10;86(15-16):598-603
pubmed: 19285088
Nature. 1996 Mar 21;380(6571):258-62
pubmed: 8637576
J Neurosci. 1995 Dec;15(12):8156-66
pubmed: 8613750
Neuron. 2018 Sep 19;99(6):1274-1288.e6
pubmed: 30236284
J Pharmacol Exp Ther. 2012 Oct;343(1):72-81
pubmed: 22743574
Eur J Pharmacol. 1988 Jan 27;146(1):185-6
pubmed: 2832195
Pain. 2010 Jan;148(1):107-113
pubmed: 19945794
Eur J Neurosci. 2001 Jun;13(11):2105-14
pubmed: 11422451
Life Sci. 2012 Jan 2;90(1-2):66-70
pubmed: 22100511
Exp Brain Res. 1999 Feb;124(4):395-421
pubmed: 10090653
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9691-6
pubmed: 16766653
Pain. 2016 Sep;157(9):1960-1969
pubmed: 27127846
Eur J Neurosci. 2002 Apr;15(8):1306-16
pubmed: 11994125
Physiol Rev. 2003 Jan;83(1):117-61
pubmed: 12506128
Eur J Pharmacol. 2009 Jan 14;602(2-3):283-7
pubmed: 19063879
J Pharmacol Exp Ther. 2002 Jul;302(1):264-73
pubmed: 12065726
Pain. 2016 Sep;157(9):2081-2088
pubmed: 27218869
Neuroscience. 2015 Dec 3;310:401-9
pubmed: 26415765
Brain Res. 2002 Aug 2;945(2):266-75
pubmed: 12126889

Auteurs

Jamie K Moy (JK)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Jane E Hartung (JE)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Melissa G Duque (MG)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Rob Friedman (R)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Vidhya Nagarajan (V)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Emanuel Loeza-Alcocer (E)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

H Richard Koerber (HR)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Thomas Christoph (T)

Department of Translational Science and Pain Disease Understanding, Grünenthal GmbH, Aachen, Germany.

Wolfgang Schröder (W)

Department of Translational Science and Pain Disease Understanding, Grünenthal GmbH, Aachen, Germany.

Michael S Gold (MS)

Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH